Functional characterization of rs2229094 (T>C) polymorphism in the tumor necrosis factor locus and lymphotoxin alpha expression in human retina: the Retina 4 project

Salvador Pastor-Idoate^{1,2}
 Irene Rodríguez-
 Hernández^{2,3}
 Jimena Rojas¹
 Lucia Gonzalez-Buendia¹
 Santiago Delgado-Tirado^{1,4}
 Jose Carlos López¹
 Rogelio González-
 Sarmiento^{2,3}
 Jose C Pastor^{1,4}

¹IOBA Eye Institute, University of Valladolid, Valladolid, ²Molecular Medicine Unit, Department of Medicine, ³Molecular and Cellular Cancer Biology Institute, High Council of Scientific Research, Biomedical Research Institute of Salamanca, University of Salamanca, Salamanca, ⁴Department of Ophthalmology, Hospital Clínico Universitario, Valladolid, Spain

Purpose: The objective of this study is to determine the expression and localization of lymphotoxin alpha (LTA) in human retinas and the functionality of one of its polymorphisms rs2229094 (C13R) (T>C), previously associated with proliferative vitreoretinopathy (PVR) development.

Materials and methods: Total RNA from three healthy human retinas were extracted and subjected to reverse transcription-polymerase chain reaction (RT-PCR) analysis, using flanking primers of LTA cDNA. In addition, three human eyes with retinal detachment (RD) and three healthy control eyes were subjected to immunohistochemistry (IHC) with a specific antibody against LTA. The functionality of T and C alleles was assessed by using pCEFL-Flag expression vector and transient transfection assays in COS-1 cell line. In addition, expression analysis by RT-PCR, Western blot and subcellular localization of both alleles and by immunofluorescence assay was performed.

Results: RT-PCR analysis revealed no significant levels of messenger RNA (mRNA) LTA in healthy human retinas. Sequential IHC staining showed differences between healthy human and RD retinas. No differences in mRNA and protein expression levels and in subcellular localization between both alleles were found. Both alleles were located in the cytoplasm of COS-1 cells.

Conclusion: Although results suggest lack of functionality, the differences found in IHC study and its strong association with PVR and its relationship with tumor necrosis factor locus, warrant further studies and could justify the use of this polymorphism as a valid biomarker to identify high-risk patients to develop PVR after RD.

Keywords: proliferative vitreoretinopathy, lymphotoxin alpha, tumor necrosis factor alpha, inflammation, cytokines, polymorphism

Introduction

Proliferative vitreoretinopathy (PVR) is the major cause of failure in retinal detachment (RD) surgery,¹ affecting 5%–10% of RD and accounting for ~75% of all primary failures after RD surgery.^{1–3} PVR is a multifactorial disease^{4–9} considered as an abnormal wound-healing process induced by a retinal break, whereupon the levels of certain inflammatory cytokines (eg, tumor necrosis factor-alpha [TNFα]) and growth factors (eg, transforming growth factor beta [TGFβ], connective tissue growth factor or platelet-derived growth factor) are increased and may play an important role in its pathogenesis.^{2,4,5,10–13}

Correspondence: Rogelio González-Sarmiento
 Unidad de Medicina Molecular,
 Departamento de Medicina, Universidad
 de Salamanca, 58-182 Paseo de San
 Vicente, 37007 Salamanca, Spain
 Tel +34 9 2329 4553
 Fax +34 9 2329 4593
 Email gonzalez@usal.es

The identification of single-nucleotide polymorphisms (SNPs) has an important implication in human diseases. They may help to assess the genetic susceptibility for certain diseases, either as a causative factor, a protective factor, or as a biomarker of the disease. Furthermore, the severity of inflammatory conditions and the circulating levels of some cytokines could be partially determined by related SNP.¹⁴ Thus, research focused on predictive molecular risk factors (biomarkers) of PVR susceptibility has been intensified in the recent years.

Lymphotoxin alpha (LTA), a member of the TNF family of cytokines, was initially isolated on the basis of an antitumor activity. Later, this cytokine was shown to have inflammatory and immunologic activities.¹⁵

A candidate gene association study, in which ~200 SNPs in 30 genes were analyzed, found a strong association between TNF locus and PVR.¹⁶ These results have been confirmed recently in an independent sample.¹⁷ Among those SNPs significantly associated with PVR, the rs2229094 was particularly of interest. First, within the LTA gene, located in the TNF locus (6p21.3), the LTA rs2229094 SNP encodes a cysteine to arginine change in the signal peptide (both amino acids with a remarkable different hydropathy profile). Second, it showed a single significant association with PVR and also it was present in every haplotypic significant association.⁵ In addition, it was not present in any nonsignificant association.⁵ Third, when predictive models of PVR based on genetic variables were analyzed, the rs2229094 showed the highest individual predictor value.¹⁶ Finally, each allelic variant showed different hydropathy profile, different prediction of the transmembrane region and different quality of the splicing probability.⁵

Despite its shown association, the functionality of this SNP and the role of LTA in human retinas and in PVR pathogenesis remain to be determined. Hence, the purpose of this study was to characterize the functionality of rs2229094 SNP and determine the expression and localization of LTA in human retinas as part of the project named Retina 4.

Materials and methods

All tissue samples were used in accordance with applicable laws for research involving human tissues and samples (14/2007 of Biomedical Research) and the Declaration of Helsinki. The study was approved by the research committee of the IOBA, Eye Institute (University of Valladolid, Valladolid, Spain) and by the ethics committee of the Valladolid Clinic University Hospital (Valladolid, Spain).

Human samples

Three postmortem eyeballs from the Regional tissue bank (Castilla y León, Spain) from subjects with no reported history of eye disease within the age range of 40–60 years and two peripheral blood samples from healthy donors were obtained for RNA extraction. Eyes were transported on dry ice to the laboratory where, under aseptic conditions, each eyeball was bisected with scissors, dividing the ocular globe into anterior and posterior eye-cups. The vitreous was removed, and the posterior eyecup was placed into a dish with clean transport medium. A paintbrush was used to mechanically detach the neuroretina from the retinal pigment epithelium layer. In addition, three human eye globe specimens diagnosed with RD during the period 1990–2013 selected from the collection of the IOBA's Ocular Pathology Laboratory (University of Valladolid, Spain) and three healthy eyes from the eye tissue bank were fixed in formalin and embedded in paraffin for immunohistochemistry (IHC) analysis. Normal adult human brain sections from the hippocampal area, provided by the Fundación Centro de Investigación en Enfermedades Neurológicas (CIEN) tissue bank (Madrid, Spain), were used as a positive control for the IHC study.

RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA from three postmortem neuroretinas and two peripheral blood samples of human subjects was isolated using Trizol reagent (Invitrogen™, Carlsbad, CA, USA) according to manufacturer protocol. RNA concentration was determined by spectrophotometry on a Nanodrop (Thermo Scientific, Waltham, MA, USA). cDNA was synthesized with the Improm-II™ Reverse Transcription System (Promega, Madison, WI, USA) according to manufacturer specifications, with 1 µg total RNA per reaction. LTA cDNA was amplified from these samples with GoTaq Hot Start Polymerase (Promega) using flanking primers 5'-ATGACACCACCTGAACGTCTC-3' (forward) and 5'-CTACAGAGCGAAGGCTCCAA-3' (reverse) following the protocol: denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 58°C for 30 seconds and polymerization at 72°C for 1 minute. The glyceraldehyde-3-phosphate dehydrogenase expression levels in each sample were used as internal control using 5'-CCACCCATGGCAAATTCCATGGCA-3' (forward) and 5'-TCTAGACGGCAGGTCAGGTCCACC-3' (reverse) primers. PCR products were separated by electrophoresis in TBE agarose gels, and LTA RT-PCR

products were sequenced to identify the different LTA transcripts obtained, and the LTA rs2229094 genotype of the LTA full-length of each sample in an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Generation of LTA expressing vectors

Complete cDNA carrying LTA rs2229094 allele C was amplified from a peripheral blood sample with primers containing EcoRI and NotI sites: 5'-GAATTCACAC CACCTGAACG-3' (forward) and 5'-GCGGCCG CCTACAGAGCGAAGG-3' (reverse) (restriction sites are underlined) following the program described previously. The product was cloned in frame with an aminoterminal Flag epitope into the EcoRI-NotI sites of mammalian vector pCEFL-Flag to generate pCEFL-Flag-LTA-C. The polymorphic substitution rs2229094 was introduced in pCEFL-Flag-LTA-C with the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA, USA) using the following primers: 5'-CTCCCAAGGGTGTGTGGCACCACCC-3' (forward) and 5'-GGGTGGTGCCACACACCCCTTGG GAG-3' (reverse) to generate pCEFL-Flag-LTA-T. All vectors were transformed in *Escherichia coli* DH5 α , and plasmid DNA was purified using the Rapid DNA plasmid miniprep kit (Genedan, S.L., Barcelona, Spain). All constructs were verified by automated sequencing.

Cell culture and DNA transfections

COS-1 cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin at 37°C in a humidified 5% CO₂ atmosphere. Exponentially, growing COS-1 cells were transiently co-transfected with 1 μ g total plasmid DNA (pCEFL-Flag-LTA-C and pCEFL-Flag-LTA-T) using X-tremeGENE HP DNA Transfection Reagent (Roche, Switzerland) at ratio 3:1. After 24–48 hours, cells were harvested to assess expression at RNA and protein level of pCEFL-Flag-LTA-C and pCEFL-Flag-LTA-T vectors by RT-PCR and Western blot. RT-PCR was performed as described previously.

Western blot

COS-1 cells were harvested 24–48 hours after transfection and resuspended in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA and 1% NP40) supplemented with Complete Mini (Roche, Switzerland) for protein extraction. Protein concentrations were determined using the BCA Protein

Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Protein extracts (200 μ g) were fractionated by sodium dodecyl-sulfate polyacrylamide gel electrophoresis, transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA) and incubated with primary specific antibodies anti-Flag M2 and anti- β -actin (Sigma-Aldrich Co., St Louis, MO, USA). The ECL Plus detection System (GE Healthcare, Buckinghamshire, UK) with HRP-conjugated anti-mouse secondary antibodies (Sigma-Aldrich Co.) was used for detection.

Confocal immunofluorescence assay

COS-1 cells were grown on glass cover-slips and transfected as indicated earlier. At 48 hours after transfection, cells were fixed with ice-cold 3.7% formaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.5% Triton X-100 in PBS and incubated with the primary antibody anti-Flag M2 (Sigma-Aldrich Co.) and the secondary antibody Alexa Fluor 488 Donkey Anti-Goat IgG conjugated to fluorescein isothiocyanate (FITC; Invitrogen). Finally, cells were stained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich Co.), and cover-slips were mounted onto microscope slides in the presence of Mowiol mounting medium. Fluorescence images were captured with a LEICA TCS SP5 DMI-6000B confocal microscope (Leica Microsystems Inc., Wetzlar, Germany) using excitation wavelength of 488 nm (for FITC) and were analyzed with LEICA LAS AF (Leica Microsystems Inc.). Final processing of images was done with the Adobe Photoshop program 6.0 (Adobe Systems Incorporated, San Jose, CA, USA).

Immunohistochemical study

The aforementioned samples were used for the IHC study. The 3 μ m sections were mounted on FLEX IHC Microscope slides (Dako, Glostrup, Denmark) and subjected to deparaffinization and hydration followed by heat-induced epitope retrieval in citrate buffer (pH 6.0). IHC staining was performed on these sections using a specific antibody against LTA (dilution 1:10; following manufacturer's instructions; reference HPA007729; Sigma-Aldrich Co.), and the reaction was visualized by the EnVision (TM FLEX detection system kit (Dako). Normal adult human brain sections from the hippocampal area were used as a positive control. Images were taken using a Leica DM4000 B light microscope equipped with a Leica DFC490 digital camera (Leica Microsystems Inc.), and final processing of images was done with the Adobe Photoshop (Adobe Systems) program. The slides were evaluated semiquantitatively in a

blind fashion by a pathologist using the following scoring system: –, negative; +, weakly positive; ++, moderately positive and +++, strongly positive.

Results

LTA messenger RNA (mRNA) expression was detected in peripheral blood but not in healthy human retinas

LTA expression was evaluated both at mRNA and protein levels by RT-PCR. LTA mRNA expression was below the significance level of the used method, and none of the three healthy human neuroretinas showed expression of LTA mRNA.

However, mRNA expression of LTA was detected in both DNA peripheral blood samples analyzed. Interestingly, RT-PCR analysis revealed different alternative LTA transcripts (Figure 1), but the analysis by sequencing of these new transcripts revealed premature stop codons, and consequently, these LTA isoforms may not have any function.

Functional characterization revealed no differences in either mRNA or protein expression levels between T and C alleles

The functionality of the T and C alleles of LTA rs2229094 polymorphism was investigated by cloning these alleles in the pCEFL-Flag expressing vector and by analyzing their expression (pCEFL-Flag-LTA-T and pCEFL-Flag-LTA-C) both at

RNA and protein levels as well as their subcellular localization in COS-1 cells using a specific anti-Flag antibody.

mRNA expression of LTA-T and LTA-C evaluated by RT-PCR at 7, 24 and 48 hours after transfection (Figure 2A) showed no differences between the two alleles. In addition, no differences were observed in the protein expression level of LTA-T and LTA-C by Western blot analysis (Figure 2B).

To investigate whether the T to C substitution in the signal peptide of LTA polymorphism may affect the corresponding protein localization, an immunofluorescence assay to study the subcellular location of the T and C LTA alleles (pCEFL-Flag-LTA-T and pCEFL-Flag-LTA-C) was performed in the COS-1 cell line at 48 hours after transfection. Both LTA alleles were located mainly in the cellular cytoplasm; however, no differences in the subcellular location between the two alleles were observed (Figure 3A and B).

LTA protein expression was detected in retinas with RD but not in healthy human retinas

Constitutive LTA protein expression was evaluated by IHC in healthy human eyes, chronic RD donor eyes and n adult human brain sections from the hippocampal area (used as a positive control). Strong positive staining for LTA was detected in control brain sections, which was confined to hippocampal neuronal cells and their cytoplasm (Figure 4A).

The intensity of the immunostaining was negative in retinal sections from healthy eyes (Figure 4B), whereas the intensity of the immunostaining and the number of stained cells were moderately positive (++) in retinal sections from chronic RD eyes (Figure 4C). The immunostaining was confined to ganglion neuron cells and their cytoplasm (Figure 4C).

Discussion

Currently, PVR is considered a multifactorial disease and thus the result of interaction between genetic and environmental factors.^{4–9} Despite the fact that the exact mechanisms responsible of PVR are not completely understood, it is widely accepted that inflammation plays an important role in its pathogenesis.^{8,18}

LTA expression and localization

TNF superfamily of cytokines regulates many physiological processes, including inflammation, proliferation, differentiation and cell death.¹⁹

The implication of proinflammatory cytokines, especially TNF α , in RD and PVR pathogenesis has been suggested in

Figure 1 RT-PCR products of LTA mRNA detected by 3% agarose gel electrophoresis stained by ethidium bromide.

Notes: mRNA expression of LTA was detected in the two peripheral blood samples from healthy subjects (lanes 1 and 2). Interestingly, RT-PCR analysis revealed different alternative LTA transcripts (A, B and C). Automatic sequencing revealed that transcript A retained introns 2 and 3 of LTA, transcript B retained intron 2, while transcript C lacked exon 3 of LTA. However, all of these three transcripts had altered reading frames and included premature stop codons, leading to truncated LTA isoforms that may have no function. GAPDH expression was used as internal control. Lane M was Φ X174 DNA/HaeIII molecular weight marker (Promega). Lane (–) was a control reaction lacking reverse transcriptase.

Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction; LTA, lymphotoxin alpha; mRNA, messenger RNA.

Figure 2 Expression analysis of T and C alleles of LTA rs2229094 polymorphism.

Notes: COSI cells were transfected with plasmids encoding LTA-C allele (pCEFL-Flag-LTA-C) and LTA-T allele (pCEFL-Flag-LTA-T). **(A)** mRNA expression of both LTA alleles was assessed by RT-PCR at 7, 24 and 48 hours after transfection. GAPDH expression was used as internal control. Lane M was Φ X174 DNA/HaeIII molecular weight marker (Promega). Lane (–) was a control reaction lacking reverse transcriptase. **(B)** Protein expression of both LTA alleles was evaluated by Western blot at 48 hours after transfection using anti-Flag antibody. Lane 1 was LTA-C allele, lane 2 was LTA-T allele and lane (–) was a negative control (not transfected COSI cells). β -Actin expression was used as internal control. No differences in RNA or protein expression levels were observed between the LTA-C and T alleles.

Abbreviations: LTA, lymphotoxin alpha; RT-PCR, reverse transcription-polymerase chain reaction.

many reports. Previous studies reported high vitreous levels of TNF α and its receptors (TNFR 1 and 2) in eyes with PVR,²⁰ and local production of TNF α has been proposed to occur in these eyes.²¹ Moreover, it has been reported that TNF α is able to mediate photoreceptor cell death after RD,^{22–24} and the addition of exogenous TNF α to organotypic culture of porcine neuroretinas has demonstrated to result in morphologic changes that resemble some of those found in human PVR.^{10,25,26}

TNF α and LTA are two molecules that play an important role in inflammation. Previous studies demonstrate that LTA, with a 40% of homology to TNF α , shares the same membrane receptors as TNF α , exerting its biological effect largely via TNF receptor 1 (TNFR1) and TNFR2 activation.²⁷ However, retinal expression and localization of LTA have not been previously described in either normal or RD eyes.

In this study, a positive immunostaining of LTA predominantly localized in the cytoplasm of ganglion cells in chronic RD eyes was observed. This particular localization (inside of

the cell) could be due probably because LTA is internalized after its receptor binding as TNF α .^{28–31} But the reason why it was only visualized in ganglion cells remains unclear.

LTA mediates its proinflammatory effects in part through the induction of adhesion molecules as vascular cell-adhesion molecule 1 and chemokine expression as monocyte chemotactic protein-1 (MCP-1).³² Increased levels of TNF α in outer nuclear layer, inner nuclear layer and MCP-1 in ganglion cell layer after a experimental RD have been reported.³³

LTA is able to act through LTA–TNFR1 complex as TNF α , but it seems to exist differences in their signal strength or capabilities.³⁴ In particular, it has been reported that LTA is less able to promote TNFR1-induced cell death and nuclear factor- κ B activation,³⁵ expression of cell surface markers³⁶ and cytokine production^{37,38} than TNF α . Alternatively, TNF α and LTA have shown protective effects in neuronal cells when acting via TNFR2, especially in ischemic conditions both in brain and in retina.^{39,40} Thus, despite LTA is able

Figure 3 Subcellular localization of T and C alleles of LTA rs2229094 polymorphism.

Notes: COSI cells were transfected with plasmids encoding LTA-C allele (pCEFL-Flag-LTAC) and LTA-T allele (pCEFL-Flag-LTAT). Forty-eight hours after transfection, confocal immunofluorescence assay was performed using anti-Flag antibody (green) and cell nuclei were stained with DAPI (blue). Both LTA-C allele **(A)** and T allele **(B)** were mainly located in the cytoplasm, without finding any differences in their cellular localization. **(C)** Not transfected COSI cells.

Abbreviations: LTA, lymphotoxin alpha; DAPI, 4',6-diamidino-2-phenylindole.

Figure 4 Immunohistochemical assay of LTA in human retina.

Notes: Immunohistochemical images of **(A)** adult human hippocampus anti-LTA staining, showing intense positivity (+++) within the cytoplasm of hippocampal neurons (black arrows), 20×. **(B)** Healthy human retina anti-LTA staining (control). Negative LTA cytoplasmic positivity (-) is observed in ganglion cells (arrowheads), 20×. **(C)** Anti-LTA staining (case) in human retina with chronic retinal detachment showing moderate cytoplasmic positivity (++) in ganglion cells (black arrows), 20×.

Abbreviations: LTA, lymphotoxin alpha; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.

to induce signals via TNFR1 and could have a crucial role in the initiation and development of some inflammatory diseases,^{41,42} due to its diverse bioactivities, it is presently not clear under which conditions LTA promotes beneficial or deleterious effects on neuronal tissues. Therefore, further studies will be critical to better understand the role of LTA in retinal neuronal cells after RD.

In this study, only three retinas suffering chronic RD and three healthy retinas could be analyzed due to the scarcity of this material, from human origin. Collecting a greater number of samples would be extremely challenging, especially samples from PVR patients. In addition, quantification of positive LTA staining was based on the impression of the pathologist, and a formal recount with consecutive serial sections was not performed, which is one of the major limitations of this study. However, to the best of our knowledge, this is the first report of LTA expression in human neuroretina.

The intensity of the immunostaining was considered moderately positive compared with positive brain section controls. RD samples used in this study presented chronic

RD and intraocular tissues were relatively disorganized, which is another limitation of this study. For this reason, they were enucleated. Thus, it is possible that in these eyes immediate proinflammatory mediators may not be present as it occurs in acute RD. In addition, the increase of neuronal cell death could be one of the possible causes leading to a smaller number of positive cells and weaker immunostaining in chronic RD eyes.

Functionality of the T and C alleles of LTA rs2229094 polymorphism

LTA gene is located on chromosome 6, between the HLA class II and class I loci. LTA gene SNPs are also shown to be associated with the inflammatory and immunomodulatory diseases including cancer.^{43–48} In addition, the contribution of TNF genes to PVR susceptibility has been previously discussed. A positive association of TNF α and LTA SNPs with PVR has been reported.^{5,17} However, the functionality of most of these SNPs remains unknown.

LTA rs2229094 SNP is a nonsynonymous polymorphism located in the signal peptide of LTA gene, which results in

a change from cysteine to arginine in codon 13 (Cys13Arg). While cysteine is a neutral hydrophobic amino acid, arginine is a hydrophilic, positively charged amino acid. Regarding the results of bioinformatic tool analysis,⁵ the hydropathy profile changed for each allelic variant could affect the function of LTA protein or modify its production or its localization, due to the hydrophobicity of the signal peptide and the asymmetric distribution of the hydrophobic and hydrophilic potentials, which determine the translocation specificity of proteins.^{49–51}

However, the functional analysis performed in this study did not show any differences in the expression levels between the LTA-T and C alleles (cysteine and arginine alleles, respectively). Furthermore, the subcellular location of C allele did not vary on the T allele, both being located in the cytoplasm, suggesting that the C allele has no significant effect in the LTA gene transcriptional regulation and subcellular location.

In this study, the times adopted for the expression analysis could not have been sufficient to prove the existence of these differences between T and C alleles. Besides, LTA gene is located within TNF locus, and it is closely linked to TNF α and lymphotoxin beta genes. Therefore, modifications derived from functional SNPs in any of these could lead to collateral alterations in the neighboring genes.⁴⁸ In addition, only three normal retinas and two peripheral blood samples could be analyzed to assess the mRNA and protein expression of LTA, due to the scarcity of this material and strict inclusion criteria in the obtention of samples.

Conclusion

Although the results suggest a lack of functionality of the LTA rs2229094 SNP, this polymorphism could remain as a valid biomarker to identify high-risk patients to develop PVR after RD, due to the strong association between PVR and LTA rs2229094 SNP previously shown by our group. In addition, we believe that differences found in the IHC studies, its strong association with PVR and its relation to TNF locus warrant further studies to clarify its potential role in RD and PVR pathogenesis.

Acknowledgments

The authors would like to thank Nieves Fernández (IOBA-University of Valladolid, Spain) for her assistance with the pictures that illustrate this work and for performing the laboratory experiments. Also, we would like to thank Fundación Centro de Investigación en Enfermedades Neurológicas (CIEN) tissue bank (Madrid, Spain) and the

Hospital Clínico Universitario (Valladolid, Spain) for providing normal adult human brain sections and human eyes from donors. This article was presented in ARVO Annual Meeting, Denver, CO, May 2014, as a poster and EVER Annual meeting, Nice, France, October 2014, as a Rapid Fire. RGS is supported by SAF 2007-66394, FIS PI13/01741 and Group of Excellence Grant (GR15) from Junta de Castilla y León. The funding organization had no role in the design or conduct of this research.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. *Am J Ophthalmol*. 1991;112(2):159–165.
2. Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. *Prog Retin Eye Res*. 2002;21(1):127–144.
3. de la Rúa ER, Pastor JC, Fernandez I, et al. Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1. *Br J Ophthalmol*. 2008;92(4):523–525.
4. Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernández MI. Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. *Acta Ophthalmol Scand*. 2006;84(3):309–313.
5. Rojas J, Fernandez I, Pastor JC, et al. A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the Retina 4 project. *Ophthalmology*. 2010;117(12):2417.e1–e2–2423.e1–e2.
6. Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, et al. The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 project. *Ophthalmology*. 2013;120(3):623–628.
7. Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, et al. The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy. *PLoS One*. 2013;8(12):e82283.
8. Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. *Prog Retin Eye Res*. 2016;51:125–155. Review.
9. Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, et al. BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project. *Acta Ophthalmol*. 2015;93(7):e541–e549.
10. Pastor JC, Méndez MC, de la Fuente MA, et al. Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. *Ophthalmic Res*. 2006;38(4):193–200.
11. Pennock S, Rheaume MA, Mukai S, Kazlauskas A. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. *Am J Pathol*. 2011;179(6):2931–2940.
12. Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. *Mediators Inflamm*. 2012;2012:815937.
13. Pennock S, Haddock LJ, Elliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? *Prog Retin Eye Res*. 2014;40:16–34.
14. Clark AG. The role of haplotypes in candidate gene studies. *Genet Epidemiol*. 2004;27(4):321–333.
15. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol*. 2003;3(9):745–756.

16. Rojas J, Fernandez I, Pastor JC, et al. Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project. *Invest Ophthalmol Vis Sci*. 2009;50(5):2384–2390.
17. Rojas J, Fernandez I, Pastor JC, et al. A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci*. 2013;54(3):1665–1678.
18. Delyfer MN, Raffelsberger W, Mercier D, et al. Transcriptomic analysis of human retinal detachment reveals both inflammatory response and photoreceptor death. *PLoS One*. 2011;6(12):e28791.
19. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell*. 2001;104(4):487–501.
20. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. *Invest Ophthalmol Vis Sci*. 2001;42(7):1586–1591.
21. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. *Br J Ophthalmol*. 1999;83(11):1296–1299.
22. Nakazawa T, Kayama M, Ryu M, et al. Tumor necrosis factor- α mediates photoreceptor death in a rodent model of retinal detachment. *Invest Ophthalmol Vis Sci*. 2011;52(3):1384–1391.
23. Murakami Y, Notomi S, Hisatomi T, et al. Photoreceptor cell death and rescue in retinal detachment and degenerations. *Prog Retin Eye Res*. 2013;37:114–140.
24. Kataoka K, Matsumoto H, Kaneko H, et al. Macrophage- and RIP3-dependent inflammasome activation exacerbates retinal detachment-induced photoreceptor cell death. *Cell Death Dis*. 2015;6:e1731.
25. Sethi CS, Lewis GP, Fisher SK, et al. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci*. 2005;46(1):329–342.
26. Fernandez-Bueno I, Fernandez-Bueno I, Garcia-Gutierrez MT, Gayoso MJ, Gonzalo-Orden JM, Pastor JC. Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor α in an organotypic culture of porcine neuroretina. *Mol Vis*. 2013;19:894–903.
27. Naoum JJ, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lymphotoxin- α and cardiovascular disease: clinical association and pathogenic mechanisms. *Med Sci Monit*. 2006;12(7):RA121–RA124.
28. Bradley JR, Thiru S, Pober JS. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. *Am J Pathol*. 1995;146(1):27–32.
29. Botchkina GI, Meistrell ME 3rd, Botchkina IL, Tracey KJ. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. *Mol Med*. 1997;3(11):765–781.
30. Schutze S, Machleidt T, Adam D, et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. *J Biol Chem*. 1999;274(15):10203–10212.
31. Tezel G, Li LY, Patil RV, Wax MB. TNF- α and TNF- α receptor-1 in the retina of normal and glaucomatous eyes. *Invest Ophthalmol Vis Sci*. 2001;42(8):1787–1794.
32. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin α 3 induces chemokines and adhesion molecules: insight into the role of LT α in inflammation and lymphoid organ development. *J Immunol*. 1998;161(12):6853–6860.
33. Nakazawa T, Matsubara A, Noda K, et al. Characterization of cytokine responses to retinal detachment in rats. *Mol Vis*. 2006;12:867–878.
34. Etemadi N, Holien JK, Chau D, et al. Lymphotoxin α induces apoptosis, necroptosis and inflammatory signals with the same potency as tumour necrosis factor. *FEBS J*. 2013;280(21):5283–5297.
35. Chaturvedi MM, LaPushin R, Aggarwal BB. Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response. *J Biol Chem*. 1994;269(20):14575–14583.
36. Andrews JS, Berger AE, Ware CF. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma. *J Immunol*. 1990;144(7):2582–2591.
37. Broudy VC, Harlan JM, Adamson JW. Disparate effects of tumor necrosis factor- α /cachectin and tumor necrosis factor- β /lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. *J Immunol*. 1987;138(12):4298–4302.
38. Oster W, Lindemann A, Horn S, Mertelsmann R, Herrmann F. Tumor necrosis factor (TNF)- α but not TNF- β induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. *Blood*. 1987;70(5):1700–1703.
39. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor α in brain injury. *Cytokine Growth Factor Rev*. 1999;10(2):119–130.
40. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. *J Neurosci*. 2002;22(7):RC216.
41. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α ? *Ann Rheum Dis*. 2004;63(10):1344–1346.
42. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. *Cytokine*. 2011;53(2):207–214.
43. Garrote JA, Arranz E, Telleria JJ, Castro J, Calvo C, Blanco-Quirós A. TNF α and LT α gene polymorphisms as additional markers of celiac disease susceptibility in a DQ2-positive population. *Immunogenetics*. 2002;54(8):551–555.
44. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454(7203):436–444.
45. Balkwill F. Tumour necrosis factor and cancer. *Nat Rev Cancer*. 2009;9(5):361–371.
46. Drutskaia MS, Efimov GA, Kruglov AA, Kuprash DV, Nedospasov SA. Tumor necrosis factor, lymphotoxin and cancer. *IUBMB Life*. 2010;62(4):283–289.
47. Lu R, Dou X, Gao X, Zhang J, Ni J, Guo L. A functional polymorphism of lymphotoxin- α (LTA) gene rs909253 is associated with gastric cancer risk in an Asian population. *Cancer Epidemiol*. 2012;36(6):e380–e386.
48. Huang Y, Yu X, Wang L, et al. Four genetic polymorphisms of lymphotoxin- α gene and cancer risk: a systematic review and meta-analysis. *PLoS One*. 2013;8(12):e82519.
49. Goldstein J, Lehnhardt S, Inouye M. Enhancement of protein translocation across the membrane by specific mutations in the hydrophobic region of the signal peptide. *J Bacteriol*. 1990;172(3):1225–1231.
50. Hoyt DW, Gierasch LM. Hydrophobic content and lipid interactions of wild-type and mutant OmpA signal peptides correlate with their in vivo function. *Biochemistry*. 1991;30(42):10155–10163.
51. Talmud P, Lins L, Brasseur R. Prediction of signal peptide functional properties: a study of the orientation and angle of insertion of yeast invertase mutants and human apolipoprotein B signal peptide variants. *Protein Eng*. 1996;9(4):317–321.

Clinical Ophthalmology**Publish your work in this journal**

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress